Item 16. Form 10-K Summary

4K characters. Original on sec.gov · Markdown

Item 16. Form 10-K Summary

Not applicable.

SCHEDULE II

AMPHENOL CORPORATION AND SUBSIDIARIES

VALUATION AND QUALIFYING ACCOUNTS

For the years ended December 31, 2021, 2020 and 2019

(Dollars in millions)


	Balance at		Charged to				Balance at
	beginning		cost and		Additions		end of
	of period		expenses		(Deductions)		period
Allowance for doubtful accounts:
Year ended December 31, 2021	$	44.8	$	1.5	$	(2.8)	$	43.5
Year ended December 31, 2020		33.6		8.5		2.7		44.8
Year ended December 31, 2019		33.5		1.2		(1.1)		33.6

Valuation allowance on deferred tax assets:
Year ended December 31, 2021	$	40.1	$	6.3	$	(1.5)	$	44.9
Year ended December 31, 2020		35.2		3.8		1.1		40.1
Year ended December 31, 2019		34.7		0.2		0.3		35.2

Signatures

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized in the Town of Wallingford, State of Connecticut on the 9th day of February, 2022.


	AMPHENOL CORPORATION


	/s/ R. Adam Norwitt
	R. Adam Norwitt
	President and Chief Executive Officer

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.


Signature	Title	Date


/s/ R. Adam Norwitt	President, Chief Executive Officer and Director	February 9, 2022
R. Adam Norwitt	(Principal Executive Officer)

/s/ Craig A. Lampo	Senior Vice President and Chief Financial Officer	February 9, 2022
Craig A. Lampo	(Principal Financial Officer and Principal Accounting Officer)

/s/ Martin H. Loeffler	Chairman of the Board of Directors	February 9, 2022
Martin H. Loeffler

/s/ David P. Falck	Presiding Director	February 9, 2022
David P. Falck

/s/ Nancy A. Altobello	Director	February 9, 2022
Nancy A. Altobello

/s/ Stanley L. Clark	Director	February 9, 2022
Stanley L. Clark

/s/ John D. Craig	Director	February 9, 2022
John D. Craig

/s/ Edward G. Jepsen	Director	February 9, 2022
Edward G. Jepsen

/s/ Rita S. Lane	Director	February 9, 2022
Rita S. Lane

/s/ Robert A. Livingston	Director	February 9, 2022
Robert A. Livingston

/s/ Anne Clarke Wolff	Director	February 9, 2022
Anne Clarke Wolff

Previous: Item 15. Exhibit and Financial Statement Schedules